Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Metabolic disorder models

Metabolic diseases represent a growing health burden to society. At Sygnature, our strong history of performing high quality in vivo pharmacology investigations (formerly under the name RenaSci) in the growing metabolic space ranging from insulin resistance to diabetic complications means we are well equipped to guide the right choice of translatable models and necessary endpoints.

We have hands-on experience with most established genetic, surgical, and dietary- or chemically-induced models of Metabolic Disorders including:

  • In mouse: lean, DIO, ob/ob, db/db, STZ/HFD and more
  • In rat: lean, weight-gain, glucocorticoid-induced insulin resistance, DIO, ZDF, STZ/HFD and more

 The table summarizes main characteristics of Metabolic models:

Therapeutic Indication Models Characteristics
Obesity Normal / lean mice and rats Non-obese, insulin sensitive
Dietary-induced obese (DIO) mice and rats Excess adiposity, moderate insulin resistance, steatosis
Insulin resistance Glucocorticoid-induced insulin resistance Insulin resistance, non-obese, rapid onset
Dietary-induced obese (DIO) mice and rats Moderate insulin resistance, excess adiposity, steatosis
ob/ob mouse model Severe insulin resistance, excess adiposity, hyperphagia
Type I diabetes Streptozotocin (STZ) high fat diet (HFD) model Insulin deficiency, hyperglycaemia, nephropathy, neuropathy
Type II diabetes db/db mouse model Progressive diabetes, hyperphagia, hyperglycaemia, insulin resistance, neuropathy, nephropathy
ZDF rat model


The study design elements for assessing novel drug potential include:

Latest News

View All

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’